SCYNEXIS, Inc. Increase (Decrease) in Accounts Payable
SCYNEXIS, Inc. (SCYX) reported Increase (Decrease) in Accounts Payable of $434.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-10
- SCYNEXIS, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$472.00K, a 124.69% decline year-over-year.
- SCYNEXIS, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $906.00K.
- SCYNEXIS, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$1.24M.
- SCYNEXIS, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$2.71M.
- SCYNEXIS, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$2.23M.
- SCYNEXIS, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$2.65M, a 326.11% decline from fiscal 2023.
- SCYNEXIS, Inc. increase (decrease) in accounts payable for fiscal 2023 was $1.17M.
- SCYNEXIS, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$1.48M, a 153.60% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$472.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $434.00K 10-Q · filed 2026-08-10 | -$808.00K derived: sum of 3 quarters · filed 2026-08-10 | -$3.51M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $906.00K 10-Q · filed 2026-05-11 | -$336.00K derived: sum of 2 quarters · filed 2026-05-11 | -$3.04M derived: sum of 3 quarters · filed 2026-05-11 | -$1.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$3.95M derived: sum of 2 quarters · filed 2026-03-04 | -$2.04M derived: sum of 3 quarters · filed 2026-08-10 | -$2.23M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$793.00K derived: sum of 2 quarters · filed 2026-08-10 | -$992.00K 10-Q · filed 2025-11-05 | -$1.48M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.71M 10-Q · filed 2026-08-10 | $1.23M derived: sum of 3 quarters · filed 2026-08-10 | $822.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$199.00K 10-Q · filed 2026-05-11 | -$683.00K derived: sum of 2 quarters · filed 2026-05-11 | -$1.09M derived: sum of 3 quarters · filed 2026-05-11 | -$4.66M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$484.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$891.00K derived: sum of 2 quarters · filed 2026-03-04 | -$4.46M derived: sum of 3 quarters · filed 2026-03-04 | -$2.65M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$407.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$3.98M derived: sum of 2 quarters · filed 2025-11-05 | -$2.17M 10-Q · filed 2025-11-05 | $1.45M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$3.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.76M 10-Q · filed 2025-08-13 | $1.86M derived: sum of 3 quarters · filed 2025-08-13 | $1.93M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.81M 10-Q · filed 2025-05-15 | $5.43M derived: sum of 2 quarters · filed 2025-05-15 | $5.50M derived: sum of 3 quarters · filed 2025-05-15 | $2.99M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $3.69M derived: sum of 2 quarters · filed 2025-03-12 | $1.18M derived: sum of 3 quarters · filed 2025-03-12 | $1.17M 10-K · filed 2025-03-12 |
| 2023-09-30 | $74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$2.44M derived: sum of 2 quarters · filed 2024-11-06 | -$2.45M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.52M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$12.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$1.48M 10-K · filed 2024-03-28 | |||
| 2021-12-31 | $2.76M 10-K · filed 2023-03-31 | |||
| 2020-12-31 | -$2.60M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |